Immune checkpoint inhibitors are waging a revolutionary war on cancer, but new research challenges the central dogma of how this drug treatment works. This research, published in the prestigious Journal of Clinical Investigation, shows for the first time that often-overlooked immune cells called Natural Killer (NK) cells play a crucial role in responding to checkpoint inhibitors.
“Checkpoint inhibitors work by waking up the body’s own immune system and unleashing an immune attack on cancer cells,” explains co-senior author Dr. Michele Ardolino, a scientist at The Ottawa Hospital and assistant professor at the University of Ottawa. “For many years, everyone assumed that checkpoint inhibitors targeted immune cells called T-cells. But our research shows that they also target Natural Killer cells and these cells play a key role in the how this treatment works.”
Dr. Arolino led the study together with Dr. David Raulet, a professor at the University of California at Berkeley.
“We believe that NK cells have an important place at the table. Checkpoint therapy combined with other NK-directed immunotherapies may enable us to target many types of tumours that are currently non-responsive to available therapies.” – Dr. Raulet
“In the cancer immunotherapy field there has been a singular focus on mobilizing anti-tumor T-cells, says Dr. Raulet. “We believe that NK cells have an important place at the table. Checkpoint therapy combined with other NK-directed immunotherapies may enable us to target many types of tumours that are currently non-responsive to available therapies.”
T-cells and NK cells can both recognize and kill cancer cells, but they do so in very different ways. NK cells recognize patterns of changes on cancer cells and are the immune system’s first line of defense. A T-cell, on the other hand, recognizes a single abnormal molecule on a cancer cell and initiates a more focused attack.
In the current study, Drs. Ardolino, Raulet and their colleagues investigated the effect of checkpoint inhibitors in various mouse models of cancer. They found that checkpoint inhibitors could shrink tumours even in mice with no anti-cancer T-cells, meaning that some other kind of cell must be responding to the checkpoint inhibitors. When the mice were depleted of NK cells, it greatly reduced or eliminated the anti-cancer effect of the checkpoint inhibitors. They also showed that NK cells produce the same checkpoint receptor molecules that T cells do, inferring they can respond directly to checkpoint inhibitors.
“This research helps solve a mystery that’s been seen in the clinic, where certain cancers are very susceptible to checkpoint inhibitors even though their T-cells don’t seem to be activated.’ – Jonathan Hodgins
“This research helps solve a mystery that’s been seen in the clinic, where certain cancers are very susceptible to checkpoint inhibitors even though their T-cells don’t seem to be activated,” says co-lead author Jonathan Hodgins, a PhD student at The Ottawa Hospital and the University of Ottawa. “If we’re right, NK cells are probably being activated in these patients.”
Previously, Dr. Ardolino, worked in Dr. Raulet’s lab in California before he was recruited to The Ottawa Hospital and the University of Ottawa in 2016. Together they are now investigating approaches to further enhance the cancer-killing ability of NK cells.
“My dream is that when people come to the hospital with cancer, we’ll be able to take a biopsy and determine not only the mutations in their cancer, but also profile how their immune system is interacting with their cancer,” says Dr. Ardolino. “Then we would give the patient the immunotherapy treatments that is most likely to work for them.”